Familial Nasopharyngeal Carcinoma 6

Prognostic Factors in Nasopharyngeal Cancer 131tumor and nodal regression rates for nasopharyngeal carcinomasafter 45 Gy of radiotherapy. Int J Radiat Oncol BiolPhys 50:961–969Fang FM, Li CF, Chien CY, Rau KM, Huang HY (2007)Immunohistochemical expression of epidermal growthfactor receptor and cyclooxygenase-2 in pediatric nasopharyngealcarcinomas: no significant correlations with clinicopathologicalvariables and treatment outcomes. Int JPediatr Otorhinolaryngol 71:447–455Fang FM, Chien CY, Li CF, Shiu WY, Chen CH, Huang HY (2009)Effect of S-phase kinase-associated protein 2 expression ondistant metastasis and survival in nasopharyngeal carcinomapatients. Int J Radiat Oncol Biol Phys 73:202–207Farias TP, Dias FL, Lima RA, Kligerman J, de Sá GM, BarbosaMM, Gonçalves FB Jr (2003) Prognostic factors and outcomefor nasopharyngeal carcinoma. Arch OtolaryngolHead Neck Surg 129:794–799Feng AC, Wu MC, Tsai SY, Chan KY, Cheng SH, Wang A, ChenSS, Jian JJ, Terng SD, Huang AT (2006) Prevertebral muscleinvolvement in nasopharyngeal carcinoma. Int J RadiatOncol Biol Phys 65:1026–1035Flores AD, Dickson RI, Riding K, Coy P (1986) Cancer of thenasopharynx in British Columbia. Am J Clin Oncol 9:281–291Foote RL, Weidner N, Harris J, Hammond E, Lewis JE, Vuong T,Ang KK, Fu KK (2005) Evaluation of tumor angiogenesismeasured with microvessel density (MVD) as a prognosticindicator in nasopharyngeal carcinoma: results of RTOG9505. Int J Radiat Oncol Biol Phys 61:745–753Fournié GJ, Courtin JP, Laval F, Chalé JJ, Pourrat JP, PujazonMC, Lauque D, Carles P (1995) Plasma DNA as a marker ofcancerous cell death. Investigations in patients sufferingfrom lung cancer and in nude mice bearing human tumors.Cancer Lett 91:221–227Fujieda S, Lee K, Sunaga H, Tsuzuki H, Ikawa H, Fan GK,Imanaka M, Takenaka H, Saito H (1999) Staining of interleukin-10predicts clinical outcome in patients withnasopharyngeal carcinoma. Cancer 85:1439–1445Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K(2002) Significance of epidermal growth factor receptorand tumor associated tissue eosinophilia in the prognosisof patients with nasopharyngeal carcinoma. Auris NasusLarynx 29:175–181Genç E, Hoşal AS, Gediko lu G, Ozyar E, Sözeri B (2000)Prognostic value of p53, proliferating cell nuclear antigen,and Ki-67 expression in undifferentiated nasopharyngealcarcinomas. Otolaryngol Head Neck Surg 122:868–873Hamilton S, Venkatesan V, Matthews TW, Lewis C, Assis L(2004) Computed tomographic volumetric analysis as apredictor of local control in laryngeal cancers treated withconventional radiotherapy. J Otolaryngol 33:289–294Hara W, Loo BW Jr, Goffinet DR, Chang SD, Adler JR, Pinto HA,Fee WE, Kaplan MJ, Fischbein NJ, Le QT (2008) Excellentlocal control with stereotactic radiotherapy boost afterexternal beam radiotherapy in patients with nasopharyngealcarcinoma. Int J Radiat Oncol Biol Phys 71:393–400Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M,Suzuki K, Saitoh A, Oouchi A, Fukuda S, Himi T (2002) Aprospective, randomized trial comparing neoadjuvant chemotherapywith radiotherapy alone in patients withadvanced nasopharyngeal carcinoma. Cancer 94:2217–2223Heng DM, Wee J, Fong KW, Lian LG, Sethi VK, Chua ET, Yang TL,Khoo Tan HS, Lee KS, Lee KM, Tan T, Chua EJ (1999)Prognostic factors in 677 patients in Singapore with nondisseminatednasopharyngeal carcinoma. Cancer 86:1912–1920Henle G, Henle W (1976) Epstein–Barr virus-specific IgAserum antibodies as an outstanding feature of nasopharyngealcarcinoma. Int J Cancer 17:1–7Henle W, Henle G, Ho HC, Burtin P, Cachin Y, Clifford P, deSchryver A, de-Thé G, Diehl V, Klein G (1970) Antibodies toEpstein–Barr virus in nasopharyngeal carcinoma, otherhead and neck neoplasms and control groups. J Natl CancerInst 44:225–231Ho HC, Ng MH, Kwan HC, Chau JC (1976) Epstein–Barr virusspecificIgA and IgG serum antibodies in nasopharyngealcarcinoma. Br J Cancer 34:655–660Ho KY, Kuo WR, Chai CY, Tsai SM, Sheu SH, Wu SC, Juan KH(2001) A prospective study of p53 expression and its correlationwith clinical response of radiotherapy in nasopharyngealcarcinoma. Laryngoscope 111:131–136Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ (2000) Acomparison of the Chinese 1992 and fifth-editionInternational Union Against Cancer staging systems forstaging nasopharyngeal carcinoma. Cancer 89:242–247Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC,Chung NN, Lui LT (2001) Induction chemotherapy withmitomycin, epirubicin, cisplatin, fluorouracil, and leucovorinfollowed by radiotherapy in the treatment of locoregionallyadvanced nasopharyngeal carcinoma. J Clin Oncol19:4305–4313Hsiao JR, Jin YT, Tsai ST (2002) Detection of cell free Epstein–Barr virus DNA in sera from patients with nasopharyngealcarcinoma. Cancer 94:723–729Hsu HC, Chen CL, Hsu MM, Lynn TC, Tu SM, Huang SC (1987)Pathology of nasopharyngeal carcinoma. Proposal of anew histologic classification correlated with prognosis.Cancer 59:945–951Hsu MM, Chen JY, Chen CJ (1988) A prospective study of antibodiesto Epstein–Barr virus DNase and viral capsid antigenfor prognostication of patients with nasopharyngealcarcinoma. J Formosan Med Assoc 87:984–988Hsu MM, Huang SC, Lynn TC, Hsieh T, Tu SM (1982) The survivalof patients with nasopharyngeal carcinoma.Otolaryngol Head Neck Surg 90:289–295Hsu MM, Chiou CR, Ko JY, Sheen TS, Hong RL, Ting LL(2000) DNA content of nasopharyngeal carcinoma: anindependent prognostic indicator. Cancer Detect Prev 24:119–126Huang GW, Sunagawa M, Jie-En L, Shimada S, Gang Z, TokeshiY, Kosugi T (2000) The relationship between microvesseldensity, the expression of vascular endothelial growth factor(VEGF), and the extension of nasopharyngeal carcinoma.Laryngoscope 110:2066–2069Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, WongWL, Chan AT (2008) Plasma osteopontin, hypoxia, andresponse to radiotherapy in nasopharyngeal cancer. ClinCancer Res 14:7080–7087Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK,Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT (2009)Randomized phase II trial of concurrent cisplatin-radiotherapywith or without neoadjuvant decetaxel and cisplatin inadvanced nasopharyngeal carcinoma. J Clin Oncol 27:242–249Huncharek M, Kupelnick B (2002) Combined chemoradiationversus radiation therapy alone in locally advanced nasopharyngealcarcinoma: results of a meta-analysis of 1528 patientsfrom six randomized trials. Am J Clin Oncol 25:219–223